Published 2018 | Version v1
Book

Prostate cancer management using 68Ga-PSMA-11 and 177Lu-PSMA-617 as theranostic pairs

  • 1. Radiation Medicine Centre, Bhabha Atomic Research Centre, Mumbai (India)
  • 2. Board of Radiation Isotope Technology, Navi Mumbai (India)

Description

Prostate cancer is common cancer in elderly males. Radiolabeled prostate-specific membrane antigen (PSMA) inhibitors are excellent candidates for prostate cancer (PCa) theranostics. This paper highlights the potential of diagnosis and radionuclide therapy using PSMA targeting molecule for patients with prostate cancer. 68Ga-PSMA-11 and therapeutic doses of 177Lu-PSMA-617 could be prepared with high purity and high yield. The radiolabeled PSMA demonstrated selective accumulation and retention in prostate cancer lesions. The results of multiple therapies improved the life of patients. This investigation also helped to establish the potential of 68Ga/177Lu PSMA as theranostic pairs in the management of prostate cancer

Part of:
Proceedings of the NAARRI international conference: advanced applications of radiation technology - souvenir

Additional details

Publishing Information

Publisher
National Association for Applications of Radioisotopes and Radiation in Industry
Imprint Place
Mumbai (India)
Imprint Title
Proceedings of the NAARRI international conference: advanced applications of radiation technology - souvenir
Imprint Pagination
230 p.
Journal Page Range
p. 62

Conference

Title
NAARRI international conference - advanced applications of radiation technology
Acronym
NICSTAR-2018
Dates
5-7 Mar 2018
Place
Mumbai (India)

Optional Information